• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

New Rosacea Fighter

Article

Louisville, Ky. - A drug indicated for the treatment of periodontal disease appears to have efficacy equivalent to conventional oral therapy for rosacea but with virtually none of the side effects.

Recent Videos
Related Content
FDA Approves Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis

FDA Approves Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis

Article
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Podcast
April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report

April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Definitions and Diagnostic Criteria of Generalized Pustular Psoriasis Require Continuity, Accuracy, Researchers Report

Definitions and Diagnostic Criteria of Generalized Pustular Psoriasis Require Continuity, Accuracy, Researchers Report

Article
Comparing Devices to Assess Facial Pigmentary and Inflammatory Conditions

Comparing Devices to Assess Facial Pigmentary and Inflammatory Conditions

Article
© 2024 MJH Life Sciences

All rights reserved.